CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 52 enrolled
Drug / intervention
LCQ908 +1 moredrug
Likely dose
LCQ908 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01811472
NCT01811472Phase 2Completed
CompareCT.gov

A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group, 24-week Pilot Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in Patients With Non-alcoholic Fatty Liver Disease

Novartis Pharmaceuticals·interventional·Posted Mar 14, 2013·Updated Feb 4, 2016

In Brief

A Phase 2 clinical trial evaluating LCQ908 and placebo for Non-alcoholic Fatty Liver Disease (NAFLD). Completed, enrolled 52 participants across 11 sites.

Detailed Summary

The purpose of this study was to determine whether LCQ908 effectively lowers liver fat, as assessed by MRI and to assess its safety and tolerability profile in subjects with non-alcoholic fatty liver disease (NAFLD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-alcoholic Fatty Liver Disease (NAFLD)
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMar 14, 2013
Enrollment StartJun 1, 2013
Primary CompletionSep 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 13.3 years ago

Interventions

LCQ908drug

LCQ908 5 mg, 10 mg, 20 mg tablets

placebodrug

Matching placebo of LCQ908 5 mg, 10 mg, 20 mg tablets.